Tools We Use: Process Maps & Lean
Historically, we have used the tool of Process maps to clearly communicate any issues to all stakeholders in the process (See Process Maps section). These maps, while extensive, are easy to read, easy to understand, and clearly show any overlap or gaps in processes. They also help us in Leaning processes.
Activating & Opening Phase III Clinical Trials: A Process & Timing Study Update
“Process Mapping – Purpose, Method & Expected Results,” University of Cincinnati Academic Health Center, Center for Clinical & Translational Science & Training
Useful Serendipity: Observations of a Manufacturing Researcher in Medicine
Other Work Related to Process Maps & Lean
1. Cheng S, Dietrich M, Dilts DM (2011) “Predicting Accrual Achievement: Monitoring Accrual Milestones of NCI-CTEP Sponsored Clinical Trials,” Clin Cancer Res. 17: 1947-55. PMID:21447723
2. Dilts DM, Cheng S, Crites JS, Sander AB, Doroshow J, (2010) “Phase III Clinical Trial Development: A Process of Chutes & Ladders,” Clin Cancer Res. 16(22): 5381-89. PMID:21062928
3. Cheng S, Dietrich M, Dilts DM (2010) “A Sense of Urgency: Evaluating the Link Between Clinical Trial Development Time and the Accrual Performance of CTEP-Sponsored Studies,” Clin Cancer Res, 16(22): 5557-63. PMID:21062929
4. Dilts DM, Sander AB, Cheng S, Crites J, Ferranti L, Wu, A, Finnigan S., Friedman S, Mooney M, Abrams J, (2009) “The Steps and Time to Process Phase III Clinical Trials at the Cancer Therapy Evaluation Program,” J of Clin Oncol, 27(11): 1761-6. PMID: 19255315
5. Dilts DM, Sandler AB, Cheng S, Crites J, Ferranti L, Wu A, Gray R, MacDonald J, Marinucci D, Comis R. (2008) “Development of Clinical Trials in a Cooperative Group Setting: The Eastern Cooperative Group,” Clin Cancer Res, 14(11):3427-33. PMID: 18519773
6. Dilts DM and Sandler AB, (2006) “The “Invisible” Barriers to Clinical Trials: The impact of Structural, Infrastructural, and Procedural Barriers to Opening Oncology Clinical Trials,” J Clin Oncol, 24(28): 4545-52. PMID: 17008693
7. Dilts DM, Sandler AB, Baker M, Cheng S, George SL, Karas KS, McGuire S, Menon G, Reusch J, Sawyer D, Scoggins M, Wu A, Zhou K, Schilsky RL (2006) “Processes to Activate Phase III Clinical Trials in a Cooperative Oncology Group: The Case of the Cancer Leukemia Group B (CALGB), J Clin Oncol, 24(28): 4553-57. PMID: 17008694
8. (2014) “The Promise and Perils in Clinical Trials,” Monash University, Melbourne, Australia(August, presented twice)
9. (2014) “Observations on Cancer Research from a Non-Medical Researcher,” keynote speech, Cancer Institute of New South Wales Annual Awards Banquet(August)
10. (2014) “Overcoming the Barriers of Transparency in Clinical Trial Data Access,” ASCO National Meeting, Chicago IL(June)
11. (2013) “Prioritizing and Measuring Clinical Research,” NIH Clinical Research Subcommittee, Bethesda, MD(Sept).
12. (2013) “Cooperative Groups, Version 3.0”, Palliative Care Research Consortium meeting, Chicago, IL(Sept).
13. (2013) “A Model for Evaluating the Efficiency and Effectiveness of Clinical Research,” Medical Executive Committee, NIH, Bethesda MD(May).
14. (2011) “Process Mapping – Purpose, Method & Expected Results,” University of Cincinnati Academic Health Center, Center for Clinical & Translational Science & Training(Sept)
15. (2011) Useful Serendipity
16. (2010) “Clinical Trial and Regulatory Process Mapping, the Clinical Trials and Regulatory Pathways Working Group at the Center for Global Development,(Oct)
17. (2010) “Beyond Efficiency: A Strategic Approach to Clinical Research,” Keynote address, 10th Annual Oncore Users Group Madison, WI(Aug)
18. (2009) “The Need for Operations Management in Healthcare: The Case of Oncology Clinical Trials,” Distinguished Lecture, Supply Chain Management Area, Sir Wilfrid Laurier University(Dec)
19. (2009) “Envisioning the future: Lessons from the past(& present) in Oncology Clinical Trials”, keynote speech to Johns Hopkins Sidney Kimmel Comprehensive Cancer Center strategic retreat, Baltimore MD(Mar)
20. (2006) Dilts and Sandler
21. Ferranti L. TPHA East and Middle Grand Region Meeting, “Using LEAN in HealthCare Interactive Setting”. (2013)
22. Ferranti L. TPHA West Grand Region Meeting LEAN Principles (2013)
2. Dilts DM, Cheng S, Crites JS, Sander AB, Doroshow J, (2010) “Phase III Clinical Trial Development: A Process of Chutes & Ladders,” Clin Cancer Res. 16(22): 5381-89. PMID:21062928
3. Cheng S, Dietrich M, Dilts DM (2010) “A Sense of Urgency: Evaluating the Link Between Clinical Trial Development Time and the Accrual Performance of CTEP-Sponsored Studies,” Clin Cancer Res, 16(22): 5557-63. PMID:21062929
4. Dilts DM, Sander AB, Cheng S, Crites J, Ferranti L, Wu, A, Finnigan S., Friedman S, Mooney M, Abrams J, (2009) “The Steps and Time to Process Phase III Clinical Trials at the Cancer Therapy Evaluation Program,” J of Clin Oncol, 27(11): 1761-6. PMID: 19255315
5. Dilts DM, Sandler AB, Cheng S, Crites J, Ferranti L, Wu A, Gray R, MacDonald J, Marinucci D, Comis R. (2008) “Development of Clinical Trials in a Cooperative Group Setting: The Eastern Cooperative Group,” Clin Cancer Res, 14(11):3427-33. PMID: 18519773
6. Dilts DM and Sandler AB, (2006) “The “Invisible” Barriers to Clinical Trials: The impact of Structural, Infrastructural, and Procedural Barriers to Opening Oncology Clinical Trials,” J Clin Oncol, 24(28): 4545-52. PMID: 17008693
7. Dilts DM, Sandler AB, Baker M, Cheng S, George SL, Karas KS, McGuire S, Menon G, Reusch J, Sawyer D, Scoggins M, Wu A, Zhou K, Schilsky RL (2006) “Processes to Activate Phase III Clinical Trials in a Cooperative Oncology Group: The Case of the Cancer Leukemia Group B (CALGB), J Clin Oncol, 24(28): 4553-57. PMID: 17008694
8. (2014) “The Promise and Perils in Clinical Trials,” Monash University, Melbourne, Australia(August, presented twice)
9. (2014) “Observations on Cancer Research from a Non-Medical Researcher,” keynote speech, Cancer Institute of New South Wales Annual Awards Banquet(August)
10. (2014) “Overcoming the Barriers of Transparency in Clinical Trial Data Access,” ASCO National Meeting, Chicago IL(June)
11. (2013) “Prioritizing and Measuring Clinical Research,” NIH Clinical Research Subcommittee, Bethesda, MD(Sept).
12. (2013) “Cooperative Groups, Version 3.0”, Palliative Care Research Consortium meeting, Chicago, IL(Sept).
13. (2013) “A Model for Evaluating the Efficiency and Effectiveness of Clinical Research,” Medical Executive Committee, NIH, Bethesda MD(May).
14. (2011) “Process Mapping – Purpose, Method & Expected Results,” University of Cincinnati Academic Health Center, Center for Clinical & Translational Science & Training(Sept)
15. (2011) Useful Serendipity
16. (2010) “Clinical Trial and Regulatory Process Mapping, the Clinical Trials and Regulatory Pathways Working Group at the Center for Global Development,(Oct)
17. (2010) “Beyond Efficiency: A Strategic Approach to Clinical Research,” Keynote address, 10th Annual Oncore Users Group Madison, WI(Aug)
18. (2009) “The Need for Operations Management in Healthcare: The Case of Oncology Clinical Trials,” Distinguished Lecture, Supply Chain Management Area, Sir Wilfrid Laurier University(Dec)
19. (2009) “Envisioning the future: Lessons from the past(& present) in Oncology Clinical Trials”, keynote speech to Johns Hopkins Sidney Kimmel Comprehensive Cancer Center strategic retreat, Baltimore MD(Mar)
20. (2006) Dilts and Sandler
21. Ferranti L. TPHA East and Middle Grand Region Meeting, “Using LEAN in HealthCare Interactive Setting”. (2013)
22. Ferranti L. TPHA West Grand Region Meeting LEAN Principles (2013)